What's new? Log in Free sign up

Clene (CLNN)

Company Profile

Company profile

Ticker

CLNN, CLNNW

Exchange

Website

CEO

Mr. Robert Etherington MBA

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Mississippi Power • Alabama Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

Chelsea Worldwide Inc.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Clene Nanomedicine, Inc. • Clene Australia Pty Ltd • dOrbital, Inc. • Clene Netherlands B.V. ...

CLNN stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$53.25

Low target

$23.00

High target

$84.00

D. Boral Capital

Canaccord Genuity

Latest filings (excl ownership)

View all

Clene Improves Cash Position and Runway

Prospectus supplement for primary offering

Regulation FD Disclosure

Notice of effectiveness

Prospectus supplement

Shelf registration

CLENE REPORTS Third QUARTER 2024 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS

Quarterly report

13 Nov 24

Regulation FD Disclosure

$7.31 mm in equity / options / securities to be acquired, sold $7.31 mm, 13 investors

Latest ownership filings

View all

Vallerie McLaughlin

Shalom Jacobovitz

Matthew Kiernan

AWM Investment Company, Inc.

ARMISTICE CAPITAL, LLC

Financial summary

Financial statements Chart CLNN financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	14.70 mm	14.70 mm	14.70 mm	14.70 mm	14.70 mm	14.70 mm
Cash burn (monthly)	2.35 mm	2.29 mm	2.66 mm	3.05 mm	1.01 mm	1.97 mm
Cash used (since last report)	8.45 mm	8.25 mm	9.59 mm	11.00 mm	3.63 mm	7.10 mm
Cash remaining	6.25 mm	6.46 mm	5.11 mm	3.70 mm	11.07 mm	7.61 mm
Runway (months of cash)	2.7	2.8	1.9	1.2	11.0	3.9

Beta Read what these cash burn values mean

Financial data from Clene earnings reports.

Institutional ownership, Q2 2024

CLNN institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	1	44	-97.7%
Opened positions	0	38	EXIT
Closed positions	43	0	NEW
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	16.32 mm	3.08 bn	-99.5%
Total shares	17.74 mm	25.01 mm	-29.1%
Total puts	0.00	135.40 k	EXIT
Total calls	0.00	48.10 k	EXIT
Total put/call ratio	–	2.8	–

Largest owners	Shares	Value	Change
Vivo Opportunity Fund	17.74 mm	$16.32 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Vanguard	0.00	-2.62 mm	EXIT
Geode Capital Management	0.00	-946.53 k	EXIT
Lunt Capital Management	0.00	-512.86 k	EXIT
Scoggin Management	0.00	-500.00 k	EXIT
Alyeska Investment	0.00	-474.13 k	EXIT
MS Morgan Stanley	0.00	-338.64 k	EXIT
Laird Norton Trust	0.00	-268.58 k	EXIT
Citadel Advisors	0.00	-235.24 k	EXIT
BLK BlackRock	0.00	-180.01 k	EXIT
NTRS Northern Trust	0.00	-169.23 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CLNN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
6 Dec 24	Reed N Wilcox	Stock Options Common Stock	Grant	Acquire A	No	No	4.4	2,853	12.55 k	2,853
6 Dec 24	Matthew Kiernan	Stock Options Common Stock	Grant	Acquire A	No	No	4.4	2,853	12.55 k	2,853
6 Dec 24	Jonathon Gay	Stock Options Common Stock	Grant	Acquire A	No	No	4.4	3,673	16.16 k	3,673
6 Dec 24	Matlin David J	Stock Options Common Stock	Grant	Acquire A	No	No	4.4	5,563	24.48 k	5,563
6 Dec 24	Alison Mosca	Stock Options Common Stock	Grant	Acquire A	No	No	4.4	4,350	19.14 k	4,350

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

D. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target

D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.

Benchmark Maintains Buy on Clene, Lowers Price Target to $84

Benchmark analyst Bruce Jackson maintains Clene (NASDAQ:CLNN) with a Buy and lowers the price target from $90 to $84.

Canaccord Genuity Maintains Buy on Clene, Lowers Price Target to $83

Canaccord Genuity analyst Sumant Kulkarni maintains Clene (NASDAQ:CLNN) with a Buy and lowers the price target from $86 to $83.

HC Wainwright & Co. Reiterates Buy on Clene, Maintains $31 Price Target

D. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target

Press releases

From Benzinga Pro

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

FDA recommends that Clene leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY ALS Platform Trial to support earlier presented findingsFDA recommends a

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.